Mirati Therapeutics assumed with an Overweight at Piper Sandler

Piper Sandler analyst Joseph Catanzaro assumed coverage of Mirati Therapeutics with an Overweight rating and $45 price target. The analyst says Krazati continues to gain traction while the company’s pipelines opportunities are starting to crystalize. The firm sees opportunity for a “portfolio of best-in-class/first-in-class precision oncology assets.”